IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Mizuho Securities USA LLC

Mizuho Securities USA LLC cut its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 18.0% during the first quarter, Holdings Channel.com reports. The fund owned 13,395 shares of the medical research company’s stock after selling 2,947 shares during the period. Mizuho Securities USA LLC’s holdings in IQVIA were worth $2,362,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of the business. Atlas Capital Advisors Inc. boosted its holdings in IQVIA by 34.5% in the 1st quarter. Atlas Capital Advisors Inc. now owns 390 shares of the medical research company’s stock worth $69,000 after buying an additional 100 shares during the last quarter. Pandora Wealth Inc. acquired a new stake in IQVIA in the 1st quarter worth about $194,000. Fiduciary Family Office LLC acquired a new stake in IQVIA in the 1st quarter worth about $962,000. JPMorgan Chase & Co. lifted its stake in IQVIA by 45.7% in the 1st quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company’s stock worth $448,686,000 after purchasing an additional 798,534 shares in the last quarter. Finally, Koss Olinger Consulting LLC purchased a new position in IQVIA in the 1st quarter worth approximately $978,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, insider Keriann Cherofsky sold 549 shares of the business’s stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the transaction, the insider owned 2,910 shares in the company, valued at approximately $557,352.30. The trade was a 15.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Eric Sherbet sold 5,800 shares of the business’s stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the transaction, the insider owned 27,178 shares of the company’s stock, valued at approximately $5,165,178.90. The trade was a 17.59% decrease in their position. The disclosure for this sale can be found here. Insiders own 1.60% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on IQV shares. JPMorgan Chase & Co. decreased their target price on shares of IQVIA from $232.00 to $177.00 and set an “overweight” rating on the stock in a research note on Monday, May 19th. Hsbc Global Res lowered shares of IQVIA from a “strong-buy” rating to a “hold” rating in a research note on Friday, April 25th. Redburn Partners set a $188.00 target price on shares of IQVIA in a research note on Friday, May 23rd. Robert W. Baird lifted their price target on shares of IQVIA from $159.00 to $196.00 and gave the company a “neutral” rating in a research report on Wednesday, July 23rd. Finally, HSBC lowered shares of IQVIA from a “buy” rating to a “hold” rating and reduced their price target for the company from $260.00 to $160.00 in a research report on Friday, April 25th. Seven analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $228.62.

IQVIA Stock Performance

NYSE:IQV opened at $180.18 on Tuesday. The company has a fifty day simple moving average of $167.06 and a two-hundred day simple moving average of $168.77. The company has a market cap of $30.63 billion, a price-to-earnings ratio of 26.07, a price-to-earnings-growth ratio of 1.97 and a beta of 1.30. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $252.88.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.04. The firm had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The company’s revenue was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.64 earnings per share. As a group, equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.